Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas

By sjmartinez • October 15, 2023

Attia S, Villalobos V, Hindi N, Wagner AJ, Chmielowski B, Oakley GJ 3rd, Peterson PM, Ceccarelli M, Jones RL, Dickson MA. Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas. Cancers (Basel). 2023 Oct 6;15(19):4871. doi: 10.3390/cancers15194871. PMID: 37835565; PMCID: PMC10572019.

Tags: docetaxel, gemcitabine, Hematology/Oncology, leiomyosarcoma, olaratumab, overall survival, Progression-free survival, Publications, soft tissue sarcomas

Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer

Herbst RS, John T, Grohé C, Goldman JW, Kato T, Laktionov K, Bonanno L, Tiseo M, Majem M, Dómine M, Ahn MJ, Kowalski DM, Pérol[...]

Redefining Clinical Trial Strategic Design to Support Drug Approval in Medical Oncology

Antonarelli G, Pérez-García JM, Gion M, Rugo H, Schmid P, Bardia A, Hurvitz S, Harbeck N, Tolaney SM, Curigliano G, Llombart-Cussac A, Cortés J. Redefining[...]

Microcytosis Merits Evaluation: A Case Report of Hemoglobin S With Hereditary Persistence of Fetal Hemoglobin (HbS-HPFH Syndrome)

Daniel CE, Bejjani A. Microcytosis Merits Evaluation: A Case Report of Hemoglobin S With Hereditary Persistence of Fetal Hemoglobin (HbS-HPFH Syndrome). Cureus. 2025 Feb 10;17(2):e78827.[...]